| Market Cap | 12.57M | P/E | - | EPS this Y | 104.10% | Ern Qtrly Grth | - |
| Income | -3.68M | Forward P/E | - | EPS next Y | 1,197.40% | 50D Avg Chg | -4.00% |
| Sales | 30.48M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -31.00% |
| Dividend | N/A | Price/Book | 0.58 | EPS next 5Y | - | 52W High Chg | -66.00% |
| Recommedations | 2.00 | Quick Ratio | 2.92 | Shares Outstanding | 1.22M | 52W Low Chg | 15.00% |
| Insider Own | 0.42% | ROA | -9.91% | Shares Float | 1.12M | Beta | -1.10 |
| Inst Own | 1.13% | ROE | -15.79% | Shares Shorted/Prior | 222.32K/216.19K | Price | 0.51 |
| Gross Margin | 30.41% | Profit Margin | -12.07% | Avg. Volume | 1,389,440 | Target Price | 300.00 |
| Oper. Margin | -13.63% | Earnings Date | Nov 11 | Volume | 130,572 | Change | 2.20% |
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.